Hot topics of circulating tumor DNA testing in breast cancer
10.3760/cma.j.issn.0529-5815.2017.02.004
- VernacularTitle: 乳腺癌循环肿瘤DNA检测临床热点问题
- Author:
Yinhua LIU
1
;
Bin ZHOU
;
Ling XU
;
Ling XIN
Author Information
1. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Gene testing
- From:
Chinese Journal of Surgery
2017;55(2):95-98
- CountryChina
- Language:Chinese
-
Abstract:
The progress of gene detection technologies represented by next generation sequencing (NGS) and digital PCR laid a foundation for studies of circulating tumor DNA (ctDNA) in breast cancer. In 2014, the NGS workgroup organized by the College of American Pathologists (CAP) published the College of American Pathologists′ Laboratory Standards for Next-Generation Sequencing Clinical Tests, which provides a blueprint for the standardization of gene testing. In 2015, the Guidelines for Diagnostic Next-generation Sequencing published by the European Society of Human Genetics claimed that NGS is unacceptable in clinical practice before studies guided by guidelines are approved. Although existing studies show the benefits of ctDNA testing in disease monitoring and prognosis analyzing, we have a ways to go to normalize the procedure and build strict detection criteria.
